This week in therapeutics

Indication	Target/marker/ pathway	Summary	Licensing status	Publication and contact information
Infectious disease				
Bacterial infection	Not applicable	<p>A study in cell culture suggests that plectasin and its derivatives could help treat bacterial infections. Plectasin produced alterations in the transcriptional profile of two strains of Gram-positive bacteria that were similar cell wall biosynthesis inhibitors. <i>In vitro</i> assays showed that plectasin bound Lipid II, a bacterial cell wall precursor. Novozymes A/S did not disclose next steps, which could include evaluating optimized plectasin derivatives in animal models of bacterial infection.</p> <p>NZ2114, a plectasin derivative from Novozymes and sanofi-aventis Group, is in an undisclosed stage of development for bacterial infections.</p> <p>SciBX 3(23); doi:10.1038/scibx.2010.702 Published online June 10, 2010</p>	Compound patented; exclusively licensed to sanofi-aventis	<p>Schneider, T. <i>et al. Science</i>; published online May 27, 2010; doi:10.1126/science.1185723</p> <p>Contact: Hans-Henrik Kristensen, Novozymes A/S, Bagsvaerd, Denmark e-mail: hahk@novozymes.com</p>